How NITI Aayog Plans to Revolutionize Medical Devices
India relies heavily on imported healthcare equipment to meet its clinical needs. Therefore, NITI Aayog is actively evaluating strategic interventions to strengthen domestic medical device manufacturing. The public policy think tank recently convened a high-level consultation with industry leaders, clinicians, and researchers. Consequently, stakeholders discussed ways to lower production costs and streamline licensing hurdles across the sector.
Current Bottlenecks in Medical Device Manufacturing
Domestic manufacturers currently face a notable 10% to 15% cost disadvantage compared to global competitors. Furthermore, high capital requirements, power tariffs, and steep logistics expenses inflate overall manufacturing expenses. In addition, entrepreneurs encounter limited access to risk funding and modern testing facilities.
Regulatory delays present an equally severe challenge for entrepreneurs. Previously, establishing an approved manufacturing plant required roughly 18 months. Today, however, redundant approvals and shifting regulatory guidelines can delay facility setup for nearly four years. As a result, domestic innovators struggle to bring vital tools to Indian hospitals quickly.
Multi-Sector Collaboration to Strengthen MedTech Policy
NITI Aayog Vice Chairman Ashok Lahiri led the multi-stakeholder policy deliberations in New Delhi. Importantly, officials from the Department of Pharmaceuticals, the Health Ministry, and the Department of Science and Technology participated. Representatives from the Indian Council of Medical Research and premier engineering institutes like IIT Delhi also joined the talks.
Moreover, the Association of Indian Medical Device Industry strongly advocated for a dedicated medical device statute. Currently, medical devices fall under drug legislation, which creates administrative complexity for engineering devices. Thus, industry leaders urged the government to implement predictable regulatory timelines and targeted financial incentives. Consequently, this collaborative approach aims to align domestic output with India's long-term healthcare priorities.
Clinical Impact on Doctors and Healthcare Delivery
A resilient domestic supply chain directly benefits medical and dental practitioners across India. First, localized production can significantly reduce procurement costs for high-volume consumables and complex diagnostic instruments. In turn, lower equipment acquisition costs allow clinics and hospitals to reduce patient out-of-pocket expenses.
Additionally, domestic production shields Indian healthcare providers from global supply chain disruptions. Healthcare practitioners also gain quicker access to tailored maintenance support and prompt replacement parts. Therefore, supportive national policies will ultimately improve patient outcomes by enhancing clinical access to reliable healthcare technology through updated general practice standards.
Frequently Asked Questions
Q1: Why do domestic medical device manufacturers face cost disadvantages in India?
Indian manufacturers face high power tariffs, elevated capital costs, and substantial logistics expenses. Additionally, limited access to risk capital and advanced testing infrastructure increases total production costs.
Q2: What major regulatory reforms did industry representatives request?
Industry bodies called for a dedicated medical device law separate from pharmaceuticals. Furthermore, they requested unified approval mechanisms to reduce facility setup timelines from four years to under eighteen months.
Q3: How do domestic device manufacturing policies benefit medical practitioners?
Robust domestic manufacturing reduces device procurement costs and ensures reliable supply availability. Consequently, doctors gain dependable access to certified clinical equipment and prompt technical support as they build essential skills through comprehensive training for new doctors.
References
- NITI Aayog explores policies to boost India's medical and dental devicemanufacturing industry - ETHealthworld
- National Medical Devices Policy 2023 - Department of Pharmaceuticals, Government of India
- Medical Devices Rules, 2017 & Updates - Central Drugs Standard Control Organization (CDSCO)
